CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| 10285 | ETCTN | Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF-mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10276 | ETCTN | A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10273 | ETCTN | A Phase 1 Study of M3814 in combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10272 | NCORP-National Institutes of Health | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| 10268 | ETCTN | Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10266 | ETCTN | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10264 | ETCTN | The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10250 | ETCTN | A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10249 | ETCTN | MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial | Adult CIRB - Early Phase Emphasis | Completed |
| 10247 | ETCTN | A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia | Adult CIRB - Early Phase Emphasis | Completed |